Literature DB >> 21774295

Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.

Wichai Santimaleeworagun1, Payom Wongpoowarak, Pantip Chayakul, Sutthiporn Pattharachayakul, Pimpimon Tansakul, Kevin W Garey.   

Abstract

OBJECTIVE: To evaluate treatment outcomes in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) nosocomial infections treated with antimicrobial agent either alone or in combination. MATERIAL AND
METHOD: Clinical data were retrospectively evaluated in patients with CRAB nosocomial infections admitted to Songklanagarind Hospital, Songkhla, Thailand from January-December 2008.
RESULTS: One hundred ten patients with CRAB nosocomial infections were identified. Most patients (57.3%) had site of infection in the lower respiratory tract and the majority of them (61.8%) received a single antimicrobial agent. Crude mortality was 30%. The presumptive success rate was 60.3% (41/68) for patients given monotherapy and 81.0% (34/42) for patients given combination therapy (p = 0.024). Patients given combination therapy were more likely to have been given at least one antibiotic to which the organism was susceptible (p = 0.004). In multivariate analysis, renal impairment, bloodstream infection, and inappropriate antimicrobial regimen were independent predictors of treatment failure.
CONCLUSION: The combination therapy regimen yielded more presumptive treatment success by increasing the likelihood of an appropriate antimicrobial therapy. Additionally, inappropriate antimicrobial treatment, renal impairment, and bloodstream infection were associated with poor treatment outcomes in patients with CRAB nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21774295

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  7 in total

1.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

2.  Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations.

Authors:  Jocelyn Teo; Tze-Peng Lim; Li-Yang Hsu; Thean-Yen Tan; Suranthran Sasikala; Pei-Yun Hon; Andrea L Kwa; Anucha Apisarnthanarak
Journal:  Antimicrob Resist Infect Control       Date:  2015-01-29       Impact factor: 4.887

Review 3.  Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis.

Authors:  Gowri Raman; Esther Avendano; Samantha Berger; Vandana Menon
Journal:  BMC Infect Dis       Date:  2015-09-30       Impact factor: 3.090

4.  Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?

Authors:  Habip Gedik; Funda Simşek; Arzu Kantürk; Taner Yildirmak; Deniz Arica; Demet Aydin; Naciye Demirel; Osman Yokuş
Journal:  Ther Clin Risk Manag       Date:  2014-09-17       Impact factor: 2.423

5.  Recommendations for infection management in patients with sepsis and septic shock in resource-limited settings.

Authors:  C Louise Thwaites; Ganbold Lundeg; Arjen M Dondorp
Journal:  Intensive Care Med       Date:  2016-06-21       Impact factor: 17.440

6.  Timing of antibiotic administration and lactate measurement in septic shock patients: a comparison between hospital wards and the emergency department.

Authors:  Veerapong Vattanavanit; Theerapat Buppodom; Bodin Khwannimit
Journal:  Infect Drug Resist       Date:  2018-01-18       Impact factor: 4.003

7.  Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Sombat Leelasupasri; Wichai Santimaleeworagun; Tossawan Jitwasinkul
Journal:  J Pathog       Date:  2018-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.